Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate

Abstract

Fifty-six children and adults with urticaria pigmentosa were examined and their symptoms evaluated. Thirteen patients with cutaneous and systemic symptoms consented to participate in a blind trial and were treated for 1 month with placebo and for another month with oral disodium cromoglycate (DSCG). More than 66% of the patients noted relief of pruritus and gastrointestinal symptoms with DSCG. Reduction of wealing was less prominent. Patients have been continued on 400-800 mg of DSCG daily for up to 15 months with continuous improvement of their symptoms and no adverse effects.